Oxford Biomedica Reported Revenue Growth
The cell and gene therapy manufacturer increased revenue as it expanded global production capacity.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you trust reports of financial momentum from companies transitioning toward profitability?
Oxford Biomedica recorded £80.2 million in revenue for the six-month period ending June 30, 2025, representing a 10 percent year-on-year increase in constant currency. The company also confirmed the activation of its new GMP manufacturing facility in Durham, North Carolina.
Why it matters
The company is scaling its global contract development and manufacturing organization (CDMO) network to support 59 active programs. Improving EBITDA margins highlight its strategy to balance operational expansion with cost discipline as it eyes long-term profitability.
The firm reported an adjusted operating EBITDA loss of £2.5 million, an improvement over the £3.9 million loss recorded in the first half of 2025. This performance supports a current revenue backlog of approximately £193 million.
The players
Oxford Biomedica
A global CDMO specializing in the development and manufacture of viral vector technologies for cell and gene therapies.
The details
Oxford Biomedica operates as a CDMO—a company that provides manufacturing services to other pharmaceutical firms—specializing in viral vector production. The company recently completed its first GMP (Good Manufacturing Practice) run at its new Durham, North Carolina site, ensuring the facility meets international standards for quality and safety. This capacity expansion complements existing operations across the United Kingdom, France, and Bedford, Massachusetts.
Timeline
June 30, 2025 marked the end of the reported six-month financial period.
2030 is the target date for achieving sustainable revenue and profitability goals.
The Tech Race
Oxford Biomedica is competing to secure its position within the specialized market for viral vector production. The successful activation of its Durham facility aligns with the industry trend of scaling manufacturing capacity to meet clinical demand for gene therapies.
The activation of the Durham facility increases available manufacturing capacity for developers of cell and gene therapies. These operational updates may reduce bottleneck risks for clinical partners relying on external viral vector production pipelines.
The takeaway
The company has demonstrated steady revenue growth and narrowing losses as it scales its footprint across multiple continents. Stakeholders should watch for progress on the 2030 profitability targets and the conversion of its £193 million backlog into realized revenue.
Further reading
For more on the infrastructure supporting current medical innovation, see Biotech.
Live Poll
Do you trust reports of financial momentum from companies transitioning toward profitability?
